文献速递消化、代谢与肾脏急症重症综合管理与镇静镇痛

罗沙司他治疗长期透析患者贫血

Roxadustat Treatment for Anemia in Patients Undergoing Long-Term Dialysis.
PubMed 文献 · N Engl J Med · 2019-07-24
一句话结论在中国透析患者中,口服罗沙司他治疗贫血不劣于肠外促红细胞生成素α,且对铁代谢和血脂有额外影响。

该试验在中国将305例长期透析且已接受促红细胞生成素α治疗至少6周的患者按2:1随机分配,接受罗沙司他或促红细胞生成素α每周三次治疗26周。主要终点为基线至第23–27周平均血红蛋白变化,罗沙司他组为0.7±1.1 g/dL,促红细胞生成素α组为0.5±1.0 g/dL,差异0.2±1.2 g/dL(95%CI -0.02至0.5),达到非劣效。罗沙司他组转铁蛋白升高、血清铁维持、转铁蛋白饱和度下降减缓,总胆固醇和低密度脂蛋白胆固醇下降更明显。高钾血症和上呼吸道感染在罗沙司他组更常见,高血压在促红细胞生成素α组更常见。

要点

  • 在中国长期透析患者中,口服罗沙司他26周纠正贫血不劣于促红细胞生成素α,主要终点差异0.2±1.2 g/dL(95%CI -0.02至0.5)。
  • 两组剂量均调整至血红蛋白目标10.0–12.0 g/dL,罗沙司他组基线至第23–27周平均变化0.7±1.1 g/dL,促红细胞生成素α组0.5±1.0 g/dL。
  • 罗沙司他组转铁蛋白较促红细胞生成素α组升高0.43 g/L(95%CI 0.32至0.53),血清铁维持差异25 μg/dL(95%CI 17至33),转铁蛋白饱和度下降减缓4.2个百分点(95%CI 1.5至6.9)。
  • 第27周罗沙司他组总胆固醇较促红细胞生成素α组多降低22 mg/dL(95%CI -29至-16),低密度脂蛋白胆固醇多降低18 mg/dL(95%CI -23至-13)。
  • 罗沙司他组高钾血症和上呼吸道感染发生率更高,促红细胞生成素α组高血压发生率更高。

适用人群与场景

  • 在中国接受透析且已接受促红细胞生成素α治疗至少6周的患者。

诊断标准与关键阈值

  • 主要终点非劣效界值:罗沙司他组与促红细胞生成素α组血红蛋白变化差值的双侧95%置信区间下限大于或等于-1.0 g/dL。
  • 两组剂量调整目标血红蛋白水平为10.0–12.0 g/dL。

处置流程与药物剂量

  • 罗沙司他或促红细胞生成素α每周给药三次,持续26周。
  • 除救援治疗外,不给予肠外铁剂。
  • 两组均调整剂量以达到血红蛋白10.0–12.0 g/dL。

研究设计与关键结果

  • 在中国开展的一项试验中,305例患者随机分配(罗沙司他组204例,促红细胞生成素α组101例),256例完成26周治疗(分别为162例和94例)。
  • 基线平均血红蛋白为10.4 g/dL。
  • 罗沙司他组基线至第23–27周血红蛋白平均变化为0.7±1.1 g/dL,促红细胞生成素α组为0.5±1.0 g/dL,差异0.2±1.2 g/dL(95%CI -0.02至0.5),达到非劣效。
  • 罗沙司他组较促红细胞生成素α组转铁蛋白升高(差异0.43 g/L;95%CI 0.32至0.53),血清铁维持(差异25 μg/dL;95%CI 17至33),转铁蛋白饱和度下降减缓(差异4.2个百分点;95%CI 1.5至6.9)。
  • 第27周罗沙司他组较促红细胞生成素α组总胆固醇降低更明显(差异-22 mg/dL;95%CI -29至-16),低密度脂蛋白胆固醇降低更明显(差异-18 mg/dL;95%CI -23至-13)。
  • 罗沙司他组铁调素平均降低30.2 ng/mL(95%CI -64.8至-13.6),促红细胞生成素α组降低2.3 ng/mL(95%CI -51.6至6.2)。
  • 罗沙司他组高钾血症和上呼吸道感染发生率更高,促红细胞生成素α组高血压发生率更高。

证据类型、等级与局限

  • 研究类型:随机对照试验。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 对于已接受促红细胞生成素α治疗的长期透析贫血患者,口服罗沙司他可作为一种非劣效于促红细胞生成素α的治疗选择。
  • 使用罗沙司他时需注意高钾血症和上呼吸道感染发生率更高,使用促红细胞生成素α时需注意高血压发生率更高。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Roxadustat is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor that stimulates erythropoiesis and regulates iron metabolism. Additional data are needed regarding the effectiveness and safety of roxadustat as compared with standard therapy (epoetin alfa) for the treatment of anemia in patients undergoing dialysis.

METHODS: In a trial conducted in China, we randomly assigned (in a 2:1 ratio) patients who had been undergoing dialysis and erythropoiesis-stimulating agent therapy with epoetin alfa for at least 6 weeks to receive roxadustat or epoetin alfa three times per week for 26 weeks. Parenteral iron was withheld except as rescue therapy. The primary end point was the mean change in hemoglobin level from baseline to the average level during weeks 23 through 27. Noninferiority of roxadustat would be established if the lower boundary of the two-sided 95% confidence interval for the difference between the values in the roxadustat group and epoetin alfa group was greater than or equal to -1.0 g per deciliter. Patients in each group had doses adjusted to reach a hemoglobin level of 10.0 to 12.0 g per deciliter. Safety was assessed by analysis of adverse events and clinical laboratory values.

RESULTS: A total of 305 patients underwent randomization (204 in the roxadustat group and 101 in the epoetin alfa group), and 256 patients (162 and 94, respectively) completed the 26-week treatment period. The mean baseline hemoglobin level was 10.4 g per deciliter. Roxadustat led to a numerically greater mean (±SD) change in hemoglobin level from baseline to weeks 23 through 27 (0.7±1.1 g per deciliter) than epoetin alfa (0.5±1.0 g per deciliter) and was statistically noninferior (difference, 0.2±1.2 g per deciliter; 95% confidence interval [CI], -0.02 to 0.5). As compared with epoetin alfa, roxadustat increased the transferrin level (difference, 0.43 g per liter; 95% CI, 0.32 to 0.53), maintained the serum iron level (difference, 25 μg per deciliter; 95% CI, 17 to 33), and attenuated decreases in the transferrin saturation (difference, 4.2 percentage points; 95% CI, 1.5 to 6.9). At week 27, the decrease in total cholesterol was greater with roxadustat than with epoetin alfa (difference, -22 mg per deciliter; 95% CI, -29 to -16), as was the decrease in low-density lipoprotein cholesterol (difference, -18 mg per deciliter; 95% CI, -23 to -13). Roxadustat was associated with a mean reduction in hepcidin of 30.2 ng per milliliter (95% CI, -64.8 to -13.6), as compared with 2.3 ng per milliliter (95% CI, -51.6 to 6.2) in the epoetin alfa group. Hyperkalemia and upper respiratory infection occurred at a higher frequency in the roxadustat group, and hypertension occurred at a higher frequency in the epoetin alfa group.

CONCLUSIONS: Oral roxadustat was noninferior to parenteral epoetin alfa as therapy for anemia in Chinese patients undergoing dialysis. (Funded by FibroGen and FibroGen [China] Medical Technology Development; ClinicalTrials.gov number, NCT02652806.).

来源:N Engl J Med,查看原文。版权归原作者所有。

参考来源

  1. Chen N, Hao C, Liu BC, et al. Roxadustat Treatment for Anemia in Patients Undergoing Long-Term Dialysis. N Engl J Med. 2019. PMID: 31340116. doi:10.1056/NEJMoa1901713

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。